新诊断非小细胞肺癌患者分期脑MRI的诊断检出率
这项回顾性单机构观察性研究纳入2017年11月至2018年10月新诊断非小细胞肺癌并接受分期胸部CT和分期脑MRI的患者1712例,评估分期脑MRI的诊断检出率(脑转移患者比例)。总体检出率为11.9%,临床IA期仅0.3%,IB期3.8%,II期4.7%;腺癌13.6%高于鳞癌5.9%,EGFR突变阳性腺癌17.5%高于EGFR突变阴性腺癌10.6%(P均<.001)。
要点
- 新诊断NSCLC分期脑MRI总体脑转移检出率为11.9%(203/1712)。
- 临床IA期脑转移检出率仅0.3%(2/615),IB期3.8%(7/186),II期4.7%(8/171)。
- 腺癌检出率13.6%高于鳞癌5.9%,EGFR突变阳性腺癌17.5%高于突变阴性腺癌10.6%。
诊断标准与关键数值
- 诊断检出率定义为全部患者中脑转移患者的比例。
- 按美国癌症联合委员会分期指南第八版基于分期胸部CT进行临床分期分组。
- 总体诊断检出率为11.9%(203/1712;95%CI:10.4%,13.5%)。
- 临床IA期检出率0.3%(2/615;95%CI:0.0%,1.2%),IB期3.8%(7/186;95%CI:1.5%,7.6%),II期4.7%(8/171;95%CI:2.0%,9.0%)。
- 腺癌检出率13.6%(176/1297;95%CI:11.8%,15.6%)高于鳞状细胞癌5.9%(21/354;95%CI:3.7%,8.9%);EGFR突变阳性腺癌17.5%(85/487;95%CI:14.2%,21.1%)高于EGFR突变阴性腺癌10.6%(68/639;95%CI:8.4%,13.3%)(两者P<.001)。
临床应用与阅片要点
- 临床IA期非小细胞肺癌分期脑MRI的脑转移检出率低,为0.3%(2/615)。
- 临床IB期和EGFR突变阳性腺癌中分期脑MRI的诊断检出率较高。
- 腺癌与鳞状细胞癌、EGFR突变阳性与阴性腺癌之间的检出率差异采用χ2检验比较,并以Bonferroni校正处理分期组间多重比较。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Existing guidelines are inconsistent regarding the indications for staging brain MRI in patients with newly diagnosed, early-stage non-small cell lung cancer (NSCLC). Purpose To evaluate the diagnostic yield of staging brain MRI in the initial evaluation of lung cancer. Materials and Methods This retrospective, observational, single-institution study included patients with newly diagnosed NSCLC who underwent staging chest CT and staging brain MRI from November 2017 to October 2018. Diagnostic yield was defined as the proportion of patients with brain metastases among all patients. Yield was stratified into clinical stage groups per the eighth edition of the American Joint Committee on Cancer staging guidelines, based on staging chest CT and in adenocarcinoma with epidermal growth factor receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK) gene rearrangement. Subgroup analyses were performed on the basis of cell types and molecular markers. The χ2 test was performed to compare the diagnostic yields, and Bonferroni correction was used to account for multiple testing between stage groups. Results A total of 1712 patients (mean age, 64 years ± 10 [standard deviation]; 1035 men) were included. The diagnostic yield of staging brain MRI in newly diagnosed NSCLC was 11.9% (203 of 1712; 95% confidence interval [CI]: 10.4%, 13.5%). In clinical stage IA, IB, and II disease, the diagnostic yields were 0.3% (two of 615; 95% CI: 0.0%, 1.2%), 3.8% (seven of 186; 95% CI: 1.5%, 7.6%), and 4.7% (eight of 171; 95% CI: 2.0%, 9.0%), respectively. The diagnostic yield was higher in patients with adenocarcinoma (13.6%; 176 of 1297; 95% CI: 11.8%, 15.6%) than squamous cell carcinoma (5.9%; 21 of 354; 95% CI: 3.7%, 8.9%) and in patients with EGFR mutation-positive adenocarcinoma (17.5%; 85 of 487; 95% CI: 14.2%, 21.1%) than with EGFR mutation-negative adenocarcinoma (10.6%; 68 of 639; 95% CI: 8.4%, 13.3%) (P < .001 for both). Conclusion The diagnostic yield of staging brain MRI in clinical stage IA non-small cell lung cancer was low, but staging brain MRI had a higher diagnostic yield in clinical stage IB and epidermal growth factor receptor mutation-positive adenocarcinoma. © RSNA, 2020 Online supplemental material is available for this article.
引用
- Kim M, Suh CH, Lee SM, et al. Diagnostic Yield of Staging Brain MRI in Patients with Newly Diagnosed Non-Small Cell Lung Cancer. Radiology. 2020. PMID: 32840470. doi:10.1148/radiol.2020201194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。